
Mean forced vital capacity (FVC) at interstitial lung disease (ILD) diagnosis in EUSTAR is approximately 87
The concept of difficult-to-manage (D2M) psoriatic arthritis (PsA) has been recently proposed. Herein, we report on the prevalence, predictors and outcomes of D2M PsA. This is a prospective single-center cohort study of PsA patients initiating b/tsDMARDs from 01/01/2009 until 01/01/2025. The EULAR proposed definition for D2M PsA was applied. Baseline parameters were assessed as predictors of D2M development using multiple logistic regression models. Long-term outcomes were compared between D2M and non-D2M patients by evaluating functional progression and adverse event rates. During a median follow-up time of 3.4 years, 46/350 patients (13.1
Diethyl phthalate (DEP) is widely used in everyday consumer products and has been associated with an increased risk of rheumatoid arthritis (RA), but its potential mechanisms remain unclear. This study elucidated the potential computational links between DEP and the molecular networks implicated in RA pathogenesis. Employing a network toxicology framework, we systematically delineated DEP-related molecular networks and screened key RA targets by integrating target prediction, RA transcriptomic data mining, interpretable machine learning, and molecular docking. Following batch correction, we conducted differential expression analysis and weighted gene co-expression network analysis (WGCNA), followed by functional enrichment of the intersecting targets. Core genes were prioritized via multiple machine-learning algorithms interpreted using SHapley Additive exPlanations (SHAP). Finally, molecular docking and molecular dynamics (MD) simulations were performed to computationally assess structural binding stability. A total of 69 targets overlapping between DEP and RA were identified. Among the constructed models, the LASSO-RF sequential framework achieved optimal discrimination, with an apparent AUC of 0.9998 (95
Patients with pre-existing rheumatoid arthritis (RA) are increasingly treated with immune checkpoint inhibitors (ICIs), but RA-specific evidence on immune-related adverse events (irAEs) and survival remains limited because autoimmune disease patients were largely excluded from pivotal trials. We aimed to evaluate the risk of irAEs and overall survival (OS) in patients with pre-existing RA initiating ICIs compared with matched non-RA controls. We conducted a nationwide matched cohort study using the National Health Information Database (NHID) of the National Health Insurance Service (NHIS). Patients with RA initiating ICIs (2018–2022) were matched (1:4) to non-RA controls by age, sex, Charlson Comorbidity Index, index year, and cancer type. irAEs were defined as events requiring systemic corticosteroids with ICI interruption or discontinuation. Incidence rate ratios (IRRs) of irAEs and hazard ratios (HRs) for OS were estimated using Cox models, with cancer-specific subgroup analyses. Among 17,971 ICI-treated cancer patients, 759 with RA and 2647 matched patients without RA were included. The incidence of irAEs was comparable between groups (IRR 0.92, 95
Anti-TERF1 autoantibodies were previously identified in systemic sclerosis (SSc) sera and were associated with severe lung involvement, adding to earlier evidence that telomere dysregulation may contribute to disease pathogenesis. Nevertheless, the report of anti-TERF1 autoantibodies in SSc has not been confirmed in an independent cohort. We sought to confirm the presence of anti-TERF1 autoantibodies in patients with SSc using a novel particle-based multi-analyte technology (PMAT) and to characterize antibody specificity by epitope mapping. A comparability study assessing agreement between a research-use only (RUO) enzyme-linked immunosorbent assay (ELISA) and a RUO PMAT assay developed for detection of anti-TERF1 autoantibodies was performed on sera from 42 individuals, including 32 with SSc and 5 healthy controls. Anti-TERF1 autoantibodies were subsequently measured in a cross-sectional cohort of 381 patients, including 133 with SSc, 28 with idiopathic pulmonary fibrosis/interstitial pneumonia with autoimmune features (IPF/IPAF), 198 with other autoimmune or infectious diseases, and 22 healthy controls. Exploratory epitope mapping of the TERF1 autoantigen was performed using pooled sera to probe a custom peptide microarray. A strong correlation was observed between ELISA and PMAT assays (Spearman rho = 0.805 [95